P
Perspective Therapeutics, Inc. (CATX)
ASE – Real vaqt narxi. Valyuta: USD
3.04
+0.04 (1.33%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
3.08
+0.04 (1.32%)
Bozordan keyin: Jun 26, 2026, 7:48 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
ASE – Real vaqt narxi. Valyuta: USD
3.04
+0.04 (1.33%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
3.08
+0.04 (1.32%)
Bozordan keyin: Jun 26, 2026, 7:48 PM EDT
Perspective Therapeutics, Inc., радиоfarmatsevtika ishlab chiqaruvchi kompaniya, Qo'shma Shtatlarda saratonni davolash uchun aniq maqsadli alfa terapiyasini (TAT) ishlab chiqadi va tijoratlashtiradi. U o'zining birinchi dori nomzodi VMT-a-NETni kashf etadi va ishlab chiqadi, u operatsiya qilinmaydigan yoki metastatik somatostatin retseptor turi 2 (SSTR2) ifodalovchi neyroendokrin o'smalari bo'lgan bemorlar uchun 1/2a faza klinik sinovlarida bo'lib, Lutathera kabi beta nurlantiruvchi terapiya kabi ilgari peptid-maqsadli radiofarmterapiya olmagan; melanokortin 1 retseptoriga (MC1R) musbat bo'lgan progressiv metastatik melanomali bemorlarni ikkinchi yoki keyingi bosqichda davolash uchun 1/2a faza klinik sinovlarida bo'lgan VMT01; va fibroblastni faollashtiruvchi oqsil alfani maqsad qilgan maqsadli alfa terapiyasi PSV359. Kompaniya, shuningdek, prostata o'ziga xos membran antigeniga (PSMA) musbat bo'lgan progressiv metastatik kastratsiyaga chidamli prostata saratonini davolash uchun beta nurlantiruvchi radioligand terapiyasi Pluvicto'ni ishlab chiqadi. U gistologik tasdiqlangan melanomali va MC1R tasvirlash skanerlari musbat bo'lgan bemorlarda nivolumab bilan birgalikda [212Pb] VMT01 ning xavfsizligi va samaradorligini baholash uchun Bristol Myers Squibb bilan klinik sinov hamkorligi to'g'risidagi kelishuvga ega. Kompaniya ilgari Isoray, Inc. nomi bilan tanilgan va 2022 yil fevral oyida o'z nomini Perspective Therapeutics, Inc. ga o'zgartirgan. Perspective Therapeutics, Inc. 2004 yilda tashkil etilgan va uning shtab-kvartirasi Vashington shtatining Sietl shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Markus Puhlmann M.B.A., M.D. | Chief Medical Officer |
| Dr. Michael K. Schultz Ph.D. | Chief Science Officer |
| Mr. Amos Hedt BA, PGradDip | Chief Business Strategy Officer |
| Mr. Andrew Bright | Executive Vice President of Brachytherapy |
| Mr. Chris Nenno | General Counsel & Corporate Secretary |
| Mr. Joel David Sendek | CFO & Principal Financial Officer |
| Mr. Johan M. Spoor | CEO & Director |
| Mr. Jonathan R. Hunt | Chief Accounting Officer |
| Mr. Shane Cobb | Executive Vice President of Operations |
| Ms. Annie J. Cheng | Vice President of Investor Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-01 | 8-K | catx-20260601.htm |
| 2026-05-27 | 8-K | catx-20260527.htm |
| 2026-05-22 | 8-K | catx-20260521.htm |
| 2026-05-11 | 8-K | catx-20260511.htm |
| 2026-05-11 | 10-Q | catx-20260331.htm |
| 2026-05-04 | 8-K | catx-20260504.htm |
| 2026-04-20 | 8-K | catx-20260418.htm |
| 2026-04-16 | DEFA14A | defa14a_-_notice_card_20.htm |
| 2026-04-16 | DEF 14A | catx-20260415.htm |
| 2026-04-01 | 8-K | catx-20260401.htm |